Theradiag has received a CE mark approval for its anti cyclic citrullinated peptide (anti-CCP) in vitro diagnostic (IVD) kit in rheumatoid arthritis.
The test further expands the Fidis portfolio of diagnostic tests for auto-immunes diseases, which cut costs and analysis time with the help of Multiplex technology.
The process of detecting anti-CCP antibodies allows for highly-reliable detection of severe forms of RA through a rapid dosing and at a lower cost than the existing tests.
Theradiag CEO Michel Finance said that the new CE mark shows the company's ability to further expand its high-value IVD portfolio.
"With this new addition to the Fidis range, we position ourselves as testing and monitoring leaders in auto-immune and inflammatory diseases," Finance added.
"This anti-CCP test strengthens our in house products portfolio, in line with our development strategy."
